Literature DB >> 24615827

Roche and Novartis colluded over wet AMD drugs, says Italian regulator.

Deborah Cohen1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24615827     DOI： 10.1136/bmj.g2006

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

1.  The safety of bevacizumab and ranibizumab in clinical studies.

Authors:  Mauro De Rosa; Andrea Messori
Journal:  Int Ophthalmol       Date:  2015-02-03       Impact factor: 2.031

2.  Off-label use of bevacizumab for wet age-related macular degeneration in Europe.

Authors:  Tomas Bro; Magdalena Derebecka; Øystein Kalsnes Jørstad; Andrzej Grzybowski
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-12-30       Impact factor: 3.117

3.  Adverse gastrointestinal events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study.

Authors:  Robert J Campbell; Chaim M Bell; Susan E Bronskill; J Michael Paterson; Marlo Whitehead; Erica de L Campbell; Sudeep S Gill
Journal:  Drug Saf       Date:  2014-09       Impact factor: 5.606

Review 4.  Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.

Authors:  Sharon D Solomon; Kristina Lindsley; Satyanarayana S Vedula; Magdalena G Krzystolik; Barbara S Hawkins
Journal:  Cochrane Database Syst Rev       Date:  2014-08-29

5.  Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.

Authors:  Sharon D Solomon; Kristina Lindsley; Satyanarayana S Vedula; Magdalena G Krzystolik; Barbara S Hawkins
Journal:  Cochrane Database Syst Rev       Date:  2019-03-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.